Elicio Therapeutics, Inc.
Income Statement
| Line Item | FY2022 | FY2021 | FY2020 |
|---|---|---|---|
| Revenue | $2.3M | $28.3M | $2.9M |
| Cost of Revenue | $0 | $433.0K | $1.2M |
| Gross Profit | $2.3M | $27.9M | $1.7M |
| Gross Margin | 100.0% | 98.5% | 58.7% |
| Operating Expenses | |||
| Research & Development | $18.1M | $48.7M | $39.0M |
| SG&A Expense | $5.6M | $18.5M | $18.0M |
| Operating Income | $-23.7M | $-39.3M | $-55.3M |
| Operating Margin | -1,031.4% | -138.8% | -1,919.2% |
| Interest Expense | $3.6M | — | — |
| Pretax Income | $-38.8M | $-54.6M | $-80.1M |
| Income Tax Expense | $0 | $0 | $0 |
| Net Income | $-28.2M | $-54.6M | $-80.1M |
| Net Margin | -1,225.9% | -192.8% | -2,781.5% |
| EPS (Basic) | $-2.79 | $-0.06 | $-0.17 |
| EPS (Diluted) | $-2.79 | $-0.06 | $-0.17 |
| Shares Outstanding (Basic) | 10.1M | 903.8M | 472.4M |
| Shares Outstanding (Diluted) | 10.1M | 903.8M | 472.4M |
| Dividends Per Share | — | — | — |